IP Library Granted Patent US 9,814,706
Granted Patent B2
US 9,814,706 · App. 14/613,845 · Granted Nov 14, 2017

Hydrobromide salt of pridopidine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,814,706
App. No.
14/613,845
Granted
Nov 14, 2017
Kind
B2
Abstract

This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.

Claims (7)

1. A hydrobromide salt of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (Pridopidine) having an X-ray powder diffraction pattern with reflections corresponding to the d-spacing values 6.0, 3.8, 3.6 and 4.0.

2. The hydrobromide salt of claim 1 provided in an anhydrous form which is in a substantially crystalline form.

3. A pharmaceutical composition comprising a therapeutically effective amount of the hydrobromide salt according to claim 1 , together with one or more adjuvants, excipients, carriers and/or diluents.

4. The pharmaceutical composition of claim 3 wherein the therapeutically effective amount of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperdine (Pridopidine) is from 1 mg to 500 mg.

5. The pharmaceutical composition of claim 3 wherein the therapeutically effective amount of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperdine (Pridopidine) is from 10 mg to 100 mg.

6. The pharmaceutical composition of claim 3 wherein the therapeutically effective amount of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperdine (Pridopidine) is 45 mg.

7. The pharmaceutical composition of claim 3 wherein the therapeutically effective amount of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperdine (Pridopidine) is 67.5 mg.

Assignments (3)
CHANGE OF NAME Recorded Jul 23, 2019
From: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 049827/0527 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
To: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Reel/Frame 047716/0148 →
CHANGE OF NAME Recorded Mar 18, 2015
From: IVAX INTERNATIONAL GMBH
To: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Reel/Frame 035318/0079 →